Pemigatinib was first approved by US FDA in FGFR2 fusion/rearrangement-positive CCA in 2020 based on an single-arm phase II FIGHT-202 study with a centrally confirmed ORR of 35.5% in 107 patients [15, 16]. Here, FGFR2 is linked to cholangiocarcinoma.